National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020
USA116th CongressHR-4866| House
| Updated: 9/22/2020
Frank Pallone
Democratic Representative
New Jersey
Health, Education, Labor, and Pensions Committee, Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020 This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Subcommittee Consideration and Mark-up Session Held.
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Placed on the Union Calendar, Calendar No. 413.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-513.
Mrs. Dingell moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H4616-4618)
DEBATE - The House proceeded with forty minutes of debate on H.R. 4866.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4616-4617)
Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health
Advanced technology and technological innovationsCongressional oversightDrug safety, medical device, and laboratory regulationGovernment information and archivesHealth programs administration and fundingHealth technology, devices, suppliesHigher educationManufacturingPrescription drugsProduct development and innovationResearch administration and fundingResearch and development
National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020
USA116th CongressHR-4866| House
| Updated: 9/22/2020
National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020 This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Subcommittee Consideration and Mark-up Session Held.
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Placed on the Union Calendar, Calendar No. 413.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-513.
Mrs. Dingell moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H4616-4618)
DEBATE - The House proceeded with forty minutes of debate on H.R. 4866.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4616-4617)
Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Frank Pallone
Democratic Representative
New Jersey
Health, Education, Labor, and Pensions Committee, Health Subcommittee, Energy and Commerce Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Advanced technology and technological innovationsCongressional oversightDrug safety, medical device, and laboratory regulationGovernment information and archivesHealth programs administration and fundingHealth technology, devices, suppliesHigher educationManufacturingPrescription drugsProduct development and innovationResearch administration and fundingResearch and development